

When
a milestone in life
is marred
by depression...

Often in the mind of the lonely, widowed, depression-prone individual, she's not gaining a daughter... she's losing a son. The occasion may be marred by depression with such symptoms as feelings of sadness, incapacity, helplessness and hopelessness.

Tofranil often relieves symptoms of depression.

As maintenance therapy during the active phase of depression, it may help prevent relapse.

The use of Tofranil in patients receiving M.A.O.I.'s is contraindicated.

In patients with cardiovascular disease, hyperthyroidism or increased intraocular pressure; or in those receiving anticholinergics (including antiparkinsonism agents), thyroid medication, or antihypertensive adrenergic neuron-blocking agents; and in those in their first trimester of pregnancy, the special precautions listed in the prescribing information should be carefully observed.

Toxic reactions severe enough to require discontinuation of Tofranil are uncommon. However, for complete details, please refer to the full prescribing information.

Tofranil* Geigy
imipramine
hydrochloride

Geigy
Geigy Pharmaceuticals
Division of Geigy Chemical Corporation
Ardley, New York 10502

ing hypomanic and manic episodes) which may require dosage reduction and/or addition of a tranquilizer or temporary discontinuation of the drug; epileptiform seizures, orthostatic hypotension and substantial blood pressure fall in hypertensive patients; purpura, transient jaundice, bone marrow depression including agranulocytosis, sensitization and skin rash including photosensitization, eosinophilia, and mild withdrawal symptoms on sudden discontinuation after prolonged treatment with high doses. Occasional hormonal effects (impotence, decreased libido, and estrogenic effects) may be observed. Atropine-like effects may be more pronounced (e.g., paralytic ileus) in susceptible patients and in those using anticholinergic agents (including antiparkinsonism drugs). **Outpatient Adult Dosage:** Initially, 75 mg. daily, increased, if necessary,

to 150 or 200 mg. Maintenance dosage may be lower, 50 to 150 mg. daily, if possible. **Geriatric and Adolescent Dosage:** Initially, 30 or 40 mg. daily, which may be increased according to response and tolerance. It is usually unnecessary to exceed 100 mg. daily. A lag in therapeutic response, lasting from a few days to a few weeks, should be expected. When dosage recommendations are already being followed, increasing the dosage does not normally shorten this latency period and may increase the incidence of adverse reactions. **Availability:** Tofranil: round tablets of 25 and 50 mg.; triangular tablets of 10 mg. for geriatric and adolescent use; and ampuls, each containing 25 mg. in 2 cc. for I.M. administration. (B)45-980-C. **For complete details, please refer to the full Prescribing Information.**